IDEXX Announces Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories (NASDAQ:IDXX) has announced the launch of the first veterinary diagnostic test for detecting kidney injury in cats and dogs. The IDEXX Cystatin B Test will be included in renal health test panels and is expected to provide new clinical insights for an estimated two million patient visits annually.
June 15, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IDEXX Laboratories has launched a new diagnostic test for kidney injury in pets, which could provide new clinical insights and expand its renal testing portfolio.
The launch of the IDEXX Cystatin B Test is a significant development for the company as it expands its renal testing portfolio and addresses a large market of two million patient visits annually. This new product could potentially increase the company's revenue and strengthen its position as a leader in pet healthcare innovation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100